AN ACT to amend the public health law, in relation to requiring dihydro-
pyrimidine dehydrogenase deficiency testing for certain individuals
with cancer; to amend the insurance law, in relation to requiring
policies and contracts of insurance to include coverage for dihydropy-
rimidine dehydrogenase deficiency testing; and to amend the social
services law, in relation to the provision of dihydroxyrimidine dehyd-
rogenase deficiency testing under the medical assistance program

The People of the State of New York, represented in Senate and Assem-
by, do enact as follows:

Section 1. The public health law is amended by adding a new section

§ 2400-a. Dihydropyrimidine dehydrogenase deficiency testing. 1. For
purposes of this section the following terms shall have the following
meanings:
(a) "Antimetabolites" means a substance that interferes with the
normal metabolic processes within cells, typically by combining with
enzymes.
(b) "Dihydropyrimidine dehydrogenase deficiency" means a condition in
which the body cannot break down the nucleotides thymine and uracil.
(c) "Fluoropyrimidine" means a group of substances used to treat cancer
through chemotherapy.

2. Every physician or other authorized practitioner who provides fluo-
ropyrimidine or other antimetabolites to individuals diagnosed with
cancer shall test for dihydroxyrimidine dehydrogenase deficiency prior
to such treatment.

§ 2. Subparagraph (A) of paragraph 12-a of subsection (i) of section
3216 of the insurance law, as amended by chapter 12 of the laws of 2012,
is amended to read as follows:

EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
(A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrimidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 3. Subparagraph (A) of paragraph 12-a of subsection (l) of section 3221 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows:

(A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrimidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 4. Paragraph 1 of subsection (q-1) of section 4303 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows:

(1) Every contract issued by a medical expense indemnity corporation, a hospital service corporation or a health service corporation for delivery in this state that provides medical, major medical or similar comprehensive-type coverage and provides coverage for prescription drugs and for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrimidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 5. The social services law is amended by adding a new section 365-o to read as follows:

§ 365-o. Provision of dihydropyrimidine dehydrogenase deficiency testing. 1. The commissioner shall establish standards and guidelines for the provision of dihydropyrimidine dehydrogenase deficiency testing prior to cancer treatment through fluoropyrimidine or other antimetabolites under the medical assistance program.

2. For purposes of this section:

(a) "Antimetabolites" means a substance that interferes with the normal metabolic processes within cells, typically by combining with enzymes.
(b) "Dihydropyrimidine dehydrogenase deficiency" means a condition in which the body cannot break down the nucleotides thymine and uracil.

(c) "Fluoropyrimidine" means a group of substances used to treat cancer through chemotherapy.

§ 6. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.